Innate immunological pathways in COVID-19 pathogenesis
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Coronavirus disease 2019 (COVID-19) is a disease characterized by a profound dysregulation of the innate immune system. This knowledge has emerged from the large body of single-cell omics studies of patients with COVID-19, which have provided one of the most detailed cellular atlases of a human disease ever. However, we are only beginning to understand the innate immunological pathways that govern host defense and immunopathology in COVID-19. In this review, we discuss the emerging understanding of how SARS-CoV-2 and host-derived molecules activate specific pattern recognition receptors to elicit protective interferon responses and pathological cytokine responses, with particular focus on acute infection of the lung and lung pathophysiology in critical COVID-19. In addition, we discuss how these pathways are modulated by virus-host interactions and host stress-sensing pathways. In-depth understanding of the disease mechanisms will likely uncover specific molecular targets for the treatment of COVID-19 and other emerging viral infections. In addition, it will reveal the fine balance between beneficial protective versus pathological disease causing immune responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Endothelial cell infection and endotheliitis in COVID-19
Varga, Z., Flammer, A. J., Steiger, P., Haberecker, M., Andermatt, R., Zinkernagel, A. S., Mehra, M. R., Schuepbach, R. A., Ruschitzka, F., & Moch, H. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30937-5 · Cited by 6,358
Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19
Ackermann, M., Verleden, S. E., Kuehnel, M., Haverich, A., Welte, T., Laenger, F., Vanstapel, A., Werlein, C., Stark, H., Tzankov, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2015432 · Cited by 5,613 · cited 2×
“In addition, a high frequency of patients with critical COVID-19 develop pulmonary microthrombosis, with an elevated risk of long-term lung injury and fibrosis (5).”
BackgroundSuccinate is an inflammatory signal that induces IL-1β through HIF-1α
Tannahill, G. M., Curtis, A. M., Adamik, J., Palsson-McDermott, E. M., McGettrick, A. F., Goel, G., Frezza, C., Bernard, N. J., Kelly, B., Foley, N. H., et al. (2013) · Nature · doi:10.1038/nature11986 · Cited by 4,176
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., Péré, H., Charbit, B., Bondet, V., Chenevier-Gobeaux, C., et al. (2020) · Science · doi:10.1126/science.abc6027 · Cited by 2,984 · cited 1×
“Analysis of patient material has demonstrated similarly reduced and delayed IFN responses in SARS-CoV-2–infected individuals (77).”
BackgroundType I interferons in infectious disease
McNab, F., Mayer-Barber, K., Sher, A., Wack, A., & O'Garra, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3787 · Cited by 2,780 · cited 26×
“The observed significant aggravation of symptoms when IFNa2b treatment was initiated late (141) is likely caused by some of the proinflammatory activities of IFNs (146), particularly when added to an already inflamed airway environment.”
BackgroundInfluentialAutoantibodies against type I IFNs in patients with life-threatening COVID-19
Bastard, P., Rosen, L. B., Zhang, Q., Michailidis, E., Hoffmann, H.-H., Zhang, Y., Dorgham, K., Philippot, Q., Rosain, J., Béziat, V., et al. (2020) · Science · doi:10.1126/science.abd4585 · Cited by 2,662
Self-citationSingle-cell landscape of bronchoalveolar immune cells in patients with COVID-19
Liao, M., Liu, Y., Yuan, J., Wen, Y., Xu, G., Zhao, J., Cheng, L., Li, J., Wang, X., Wang, F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0901-9 · Cited by 2,614
An inflammatory cytokine signature predicts COVID-19 severity and survival
Del Valle, D. M., Kim-Schulze, S., Huang, H.-H., Beckmann, N. D., Nirenberg, S., Wang, B., Lavin, Y., Swartz, T. H., Madduri, D., Stock, A., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1051-9 · Cited by 2,605 · cited 2×
“Despite this, IL-1 seems to not significantly correlate with disease severity (13, 29), but so do the levels of IL-18, another inflammasome product, which promotes IFN expression (108).”
BackgroundInborn errors of type I IFN immunity in patients with life-threatening COVID-19
Zhang, Q., Bastard, P., Liu, Z., Le Pen, J., Moncada-Velez, M., Chen, J., Ogishi, M., Sabli, I. K. D., Hodeib, S., Korol, C., et al. (2020) · Science · doi:10.1126/science.abd4570 · Cited by 2,229
Self-citationComplex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
Giamarellos-Bourboulis, E. J., Netea, M. G., Rovina, N., Akinosoglou, K., Antoniadou, A., Antonakos, N., Damoraki, G., Gkavogianni, T., Adami, M.-E., Katsaounou, P., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.009 · Cited by 2,045
Interleukin-6 receptor antagonists in critically ill patients with Covid-19.
The REMAP-CAP Investigators (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100433 · Cited by 1,962
Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity
Cantuti-Castelvetri, L., Ojha, R., Pedro, L. D., Djannatian, M., Franz, J., Kuivanen, S., van der Meer, F., Kallio, K., Kaya, T., Anastasina, M., et al. (2020) · Science · doi:10.1126/science.abd2985 · Cited by 1,925
Type 2 alveolar cells are stem cells in adult lung
Barkauskas, C. E., Cronce, M. J., Rackley, C. R., Bowie, E. J., Keene, D. R., Stripp, B. R., Randell, S. H., Noble, P. W., & Hogan, B. L. M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68782 · Cited by 1,776 · cited 1×
“Last, the microenvironment in the COVID-19 lung disfavors alveolar epithelial regeneration, as evidenced by incomplete transition of progenitor AT2 to AT1 cells in COVID-19 (15, 51) as it normally occurs during lung regeneration (52).”
BackgroundFunctional exhaustion of antiviral lymphocytes in COVID-19 patients
Zheng, M., Gao, Y., Wang, G., Song, G., Liu, S., Sun, D., Xu, Y., & Tian, Z. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0402-2 · Cited by 1,768 · cited 1×
“However, at the same time they also display markers of functional exhaustion and down-regulation of genes associated with cytoxicity (39, 41, 42), thus demonstrating a central similarity to HLH (43).”
ResultKarki, R., Sharma, B. R., Tuladhar, S., Williams, E. P., Zalduondo, L., Samir, P., Zheng, M., Sundaram, B., Banoth, B., Malireddi, R. K. S., et al. (2021) · Cell · doi:10.1016/j.cell.2020.11.025 · Cited by 1,734 · cited 3×
“Mechanistically, PANoptosis was induced through Janus kinase–signal transducer and activator of transcription 1–IRF1 signaling, and the cell death was executed via caspase-8 and Fas-associated death domain protein (115).”
InfluentialProteomic and Metabolomic Characterization of COVID-19 Patient Sera
Shen, B., Yi, X., Sun, Y., Bi, X., Du, J., Zhang, C., Quan, S., Zhang, F., Sun, R., Qian, L., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.032 · Cited by 1,514
Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment
Schulte-Schrepping, J., Reusch, N., Paclik, D., Baßler, K., Schlickeiser, S., Zhang, B., Krämer, B., Krammer, T., Brumhard, S., Bonaguro, L., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.001 · Cited by 1,461
Wang, S., Song, R., Wang, Z., Jing, Z., Wang, S., & Ma, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01298 · Cited by 1,450
Vogl, T., Tenbrock, K., Ludwig, S., Leukert, N., Ehrhardt, C., van Zoelen, M. A. D., Nacken, W., Foell, D., van der Poll, T., Sorg, C., et al. (2007) · Nature Medicine · doi:10.1038/nm1638 · Cited by 1,418
Chua, R. L., Lukassen, S., Trump, S., Hennig, B. P., Wendisch, D., Pott, F., Debnath, O., Thürmann, L., Kurth, F., Völker, M. T., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0602-4 · Cited by 1,035 · cited 1×
“Last, the hyperactivation of macrophages and monocytes leads to extensive interaction with epithelial cells and T cells (18, 25, 26).”
BackgroundActivation and evasion of type I interferon responses by SARS-CoV-2
Lei, X., Dong, X., Ma, R., Wang, W., Xiao, X., Tian, Z., Wang, C., Wang, Y., Li, L., Ren, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17665-9 · Cited by 980 · cited 1×
“PATHWAYS DRIVING IFN RESPONSES AND THEIR INHIBITION BY SARS-COV-2 SARS-CoV-2 is a poor inducer of type I IFN expression in vitro, which is triggered in a delayed manner (14, 70, 73, 74).”
BackgroundEvasion of Type I Interferon by SARS-CoV-2
Xia, H., Cao, Z., Xie, X., Zhang, X., Chen, J. Y.-C., Wang, H., Menachery, V. D., Rajsbaum, R., & Shi, P.-Y. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108234 · Cited by 957 · cited 1×
“NSP13 binds and blocks the phosphorylation of the IRF3-activating kinase TBK1 (TANK-binding kinase 1) (89); the NSP3 protein PLpro (papain-like protease) has protease activity and cleaves off ISG15 from IRF3, thus impairing IRF3 activation and IFN expression (88), and NSP1 blocks IFN mRNA translation (91).”
BackgroundA dynamic COVID-19 immune signature includes associations with poor prognosis
Laing, A. G., Lorenc, A., del Molino del Barrio, I., Das, A., Fish, M., Monin, L., Muñoz-Ruiz, M., McKenzie, D. R., Hayday, T. S., Francos-Quijorna, I., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1038-6 · Cited by 946
COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas
Ren, X., Wen, W., Fan, X., Hou, W., Su, B., Cai, P., Li, J., Liu, Y., Tang, F., Zhang, F., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.053 · Cited by 865
Rodrigues, T. S., de Sá, K. S. G., Ishimoto, A. Y., Becerra, A., Oliveira, S., Almeida, L., Gonçalves, A. V., Perucello, D. B., Andrade, W. A., Castro, R., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201707 · Cited by 839
Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19
Silvin, A., Chapuis, N., Dunsmore, G., Goubet, A.-G., Dubuisson, A., Derosa, L., Almire, C., Hénon, C., Kosmider, O., Droin, N., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.002 · Cited by 834 · cited 5×
“By contrast, HLA-DRlow S100Ahigh monocytes are abundant in critical COVID-19 (21, 22).”
InfluentialT cell responses in patients with COVID-19
Chen, Z., & John Wherry, E. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0402-6 · Cited by 797 · cited 2×
“For detailed discussions of T and B cells in COVID-19, we refer to reviews published by others (3, 4).”
BackgroundMethodPresence of Genetic Variants Among Young Men With Severe COVID-19
van der Made, C. I., Simons, A., Schuurs-Hoeijmakers, J., van den Heuvel, G., Mantere, T., Kersten, S., van Deuren, R. C., Steehouwer, M., van Reijmersdal, S. V., Jaeger, M., et al. (2020) · JAMA · doi:10.1001/jama.2020.13719 · Cited by 789
HIF-1 as a target for drug development
Giaccia, A., Siim, B. G., & Johnson, R. S. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1199 · Cited by 631 · cited 1×
“In the case of HIF1, hypoxia leads to inhibition of the activity of the prolyl-hydroxylases, which normally hydroxylate HIF1 to link it to the proteasomal pathway, hence allowing accumulation of the transcription factor (69).”
BackgroundChristgen, S., Zheng, M., Kesavardhana, S., Karki, R., Malireddi, R. K. S., Banoth, B., Place, D. E., Briard, B., Sharma, B. R., Tuladhar, S., et al. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00237 · Cited by 588
Galani, I.-E., Rovina, N., Lampropoulou, V., Triantafyllia, V., Manioudaki, M., Pavlos, E., Koukaki, E., Fragkou, P. C., Panou, V., Rapti, V., et al. (2021) · Nature Immunology · doi:10.1038/s41590-020-00840-x · Cited by 503
SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation
Li, S., Zhang, Y., Guan, Z., Li, H., Ye, M., Chen, X., Shen, J., Zhou, Y., Shi, Z.-L., Zhou, P., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00334-0 · Cited by 365 · cited 1×
“This productive replication is associated with extensive cell death driven by cell apoptosis, necroptosis, and pyroptosis (27, 48), the latter potentially serving as a source of DAMPs.”
BackgroundMiao, G., Zhao, H., Li, Y., Ji, M., Chen, Y., Shi, Y., Bi, Y., Wang, P., & Zhang, H. (2021) · Developmental Cell · doi:10.1016/j.devcel.2020.12.010 · Cited by 354 · cited 1×
“However, autophagy is not only induced but also counteracted by SARS-CoV-2 (160, 161), and autophagy may exert either proviral or antiviral activities, depending on the cellular context (162), indicating possibilities for therapeutic targeting.”
BackgroundRespiratory Syncytial Virus Activates Innate Immunity through Toll-Like Receptor 2
Murawski, M. R., Bowen, G. N., Cerny, A. M., Anderson, L. J., Haynes, L. M., Tripp, R. A., Kurt-Jones, E. A., & Finberg, R. W. (2009) · Journal of Virology · doi:10.1128/jvi.00671-08 · Cited by 279
Junqueira, C., Crespo, Â., Ranjbar, S., Ingber, J., Parry, B., Ravid, S., Lacerda, L. B. D., Lewandrowski, M., Clark, S., Ho, F., et al. (2021) · doi:10.1101/2021.03.06.21252796 · Cited by 70
Metadata
- Authors
- Paludan, S. R., & Mogensen, T. H.
- Venue
- Science Immunology
- Published
- 2022-01-07
- Volume
- 7
- Issue
- 67
- Pages
- eabm5505-eabm5505
- ISSN
- 2470-9468 (ISSN-L)
- OpenAlex
- W4206541733
- Cited by
- 169
- References
- 36
- FWCI
- 11.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.